Key facts
- This page summarizes David Sidransky's Form 4 filing for Ayala Pharmaceuticals, Inc..
- 3 reported transactions and 9 derivative rows are listed below.
- Accepted by SEC: 23 Jan 2023, 17:19.
David Sidransky - 19 Jan 2023 Form 4 Insider Report for Ayala Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 19 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Jan 2023, 17:19:33 UTC
- Prior SEC filing
- 29 Dec 2022
- Next SEC filing
- 07 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Sidransky
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Sidransky filed Form 4 for Ayala Pharmaceuticals, Inc. on 23 Jan 2023.
Change
- Previous filing in this sequence was filed on 29 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADXS
transaction
Common Stock
Award
- Transaction value
- Shares
- +46
- Change %
- Price
- Shares after
- 46
- Date
- 19 Jan 2023
- Ownership
- Held by Reporting Person's Son
- Footnotes
- F1
ADXS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 93
- Date
- 19 Jan 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADXS
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +2,342
- Change %
- Price
- Shares after
- 2,342
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,342
- Exercise price
- $55.23
- Footnotes
- F2, F3
ADXS
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +2,342
- Change %
- Price
- Shares after
- 2,342
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,342
- Exercise price
- $8.70
- Footnotes
- F4, F5
ADXS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 17
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17
- Exercise price
- $16128.00
- Footnotes
- F2
ADXS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 42
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42
- Exercise price
- $15372.00
- Footnotes
- F2
ADXS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25
- Exercise price
- $9252.00
- Footnotes
- F2
ADXS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25
- Exercise price
- $3828.00
- Footnotes
- F2
ADXS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25
- Exercise price
- $648.00
- Footnotes
- F2
ADXS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 125
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125
- Exercise price
- $24.80
- Footnotes
- F2
ADXS
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 163
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 163
- Exercise price
- $52.80
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Received in exchange for 250 shares of the common stock of Ayala Pharmaceuticals, Inc. ("Old Ayala") in the merger of Old Ayala into the Issuer (the "Merger"). On the day prior to the effective date of the Merger, the closing price of Old Ayala's common stock was $0.53 per share, and the closing price of the Issuer's common stock was $2.95 per share.
Footnote F2
This option is fully vested and exercisable.
Footnote F3
Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $10.35 per share.
Footnote F4
This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.
Footnote F5
Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $1.63 per share.
Footnote F6
Two-thirds of this award is currently vested and the remaining one-third will be vested on May 4, 2023.